PCSK9 Inhibitors -Pipeline Insights, 2015” – A DelveInsight’s Report

DelveInsight, the leading market research and consulting company has added a new report “PCSK9 Inhibitors -Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Mechanism of Action Pipeline Insight.
By: DelveInsight Business Research
 
DWARKA, India - Sept. 22, 2015 - PRLog -- Introduction of frequent medical advancement leads to rewriting of the script for treating a disease or condition each time. With the announcements of impressive results of a new type of cholesterol-lowering drug, this scenario might not repeat for next few years. PCSK9 inhibitors are a new class of drug which has shown to dramatically lower LDL cholesterol levels. PCSK9 inhibitors are monoclonal antibodies, a type of biologic drug. They inactivate a protein in the liver called proprotein convertase subtilisin kexin 9 (PCSK9).

The PCSK9 Inhibitors - Pipeline Insights, 2015 report provides information of

·   25+ pipeline drugs with 17+ companies actively involved in drug development. There is 1 drug in phase III, 2 in phase II, 6 in phase I, 8 in pre-clinical and 3 in discovery.

·    Pfizer is developing a lead product Bococizumab which is in Phase III.

·    R&D activities and technologies used along with the pipeline molecules in development.

·   Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

·   Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, PCSK9 Inhibitors - Pipeline Insights, 2015 report provides the in-depth analysis of PCSK9 Inhibitors Landscape across the globe. Therefore the report on PCSK9 Inhibitors - Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on our PCSK9 Inhibitors - Pipeline Insights Reports email us at info@delveInsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Contact
DelveInsight Business Research
***@delveinsight.com
End
Source:DelveInsight Business Research
Email:***@delveinsight.com Email Verified
Tags:DelveInsight, Mechanism of Action, Collaborations
Industry:Business
Location:Dwarka - Delhi - India
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
DelveInsight News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share